# Developmental Therapeutics (DT) Program

> **NIH NIH P30** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2021 · $64,041

## Abstract

PROJECT SUMMARY/ABSTRACT (DEVELOPMENTAL THERAPEUTICS)
Members of the Developmental Therapeutics (DT) Program use breakthrough insights made in the UMCCC
basic science programs to drive the discovery of first-in-class small molecule anticancer agents that can be
advanced into biomarker-driven clinical trials. The Program serves as the forum for investigators with shared
interest in pre-clinical development of novel targets, agents, therapeutic combinations or natural product-based
drugs that either perturb protein-protein interactions, inhibit kinase activity, target epigenetic modifiers or
function as radiation sensitizers. The DT Program comprises 31 members from 18 departments and five
schools across the University of Michigan. Total annual direct research support is $15.2M, with $4.1M (27%)
from the NCI, $3M (19%) from other NIH support and $3.7M (24.2%) from other peer-reviewed sources. During
the last funding period, and in close collaboration with the Structure and Drug Screening as well as
Pharmacokinetics Shared Resources, DT Program members authored 547 publications, of which 22.1% are
intra-programmatic and 35.8% are inter-programmatic. To further these advances, DT Program research is
focused on one or more of the following Specific Aims: 1) validation of novel cancer targets that are amenable
to pharmacological intervention, 2) discovery, optimization and evaluation of therapeutic agents and potential
biomarkers of response in clinically relevant preclinical model systems, and 3) advancement of preclinical
proof-of-concept studies into biomarker-enabled clinical trials through structured collaborations between DT
Program members and TACR-based clinical investigator teams. By incorporating clinical investigators in the
design of preclinical studies at the pre-IND stage, the DT Program seeks to streamline clinical drug
development while improving the likelihood of clinical successes.
1"
"

## Key facts

- **NIH application ID:** 10198792
- **Project number:** 5P30CA046592-32
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** Judith S Leopold
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $64,041
- **Award type:** 5
- **Project period:** 1997-06-01 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10198792

## Citation

> US National Institutes of Health, RePORTER application 10198792, Developmental Therapeutics (DT) Program (5P30CA046592-32). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10198792. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*